UPDATE: Corrected to reflect that the launch was global, and not limited to the US.
The Cellvizio device is designed for use in a variety of surgical procedures, providing real time visualization at the microscopic level. The system allows the operating physician to visualize the internal microstructure of tissue in real time during ureteroscopic and cytoscopic procedures, the companies said.
“We are excited to bring Cellvizio to urologists throughout the United States. Allowing physicians to view tissue in real time offers them an opportunity to quickly determine potential options for patients,” Cook urology biz VP Jean-Marc Creissel said in a press release.
“We are pleased that our partners at Cook Medical have continued to invest in this collaboration and welcome the opportunity to increase clinical awareness within the urology community of Cellvizio’s capacity to improve patient outcomes through real-time microscopic imaging. We view urology as an important illustration of Mauna Kea’s ongoing strategy to partner with leading healthcare organizations to accelerate the global commercialization of Cellvizio in a variety of clinical applications,” Mauna Kea CEO Sacha Loiseau said in a prepared statement.
Last month, Mauna Kea said it won FDA 510(k) clearance for its CelioFlex UHD confocal miniprobes designed for use with its Cellvizio device in robotic-assisted surgery.